The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
In nine best-selling editions, Shara Rosen (MBA, RT), has created authoritative market estimates and forecasted growth models for in vitro diagnostic (IVD) testing products throughout the world. This single volume covers the entirety of the clinical testing market and all of its segments, providing customers with a tremendous value.
Used by Top IVD Companies For Business Planning.
This year, Kalorama has published its ninth edition of this informative volume based on the market events of 2013 and early 2014. New entrants, new technologies have entered the stage and all important events are cataloged in this report. The idea behind Kalorama's unique report is that the entire market can be captured in one volume. Published every two years, this volume includes market estimates for 2013 base year and forecasts to 2018 for the most important aspects of all of the major segments of clinical lab testing, including:
Independent Perspective. Authoritative Coverage.
At 1200 pages, this is the most comprehensive report on the in vitro diagnostic industry available. No surprise that it has been called the 'Bible of the IVD Industry' by past users of the report. Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments.
Understand areas of the market that might not be available in your company's internal resources. View the industry from an independent point of view. Learn about competitors in a way that may be invisible to internal personnel. Know the market players - your potential partners, your existing or potential competitors, in proper context. Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.
Worldwide Coverage, Including Emerging Markets.
From the first edition, this report has been intended to create a global picture for readers. Clinical testing is a worldwide business. This has always been true, but today emerging markets are part of the growth strategy of companies large and small. Kalorama has adjusted to these industry trends with enhanced geographic segmentation. While the US is a large healthcare market, many of the most interesting opportunities for companies are occurring in emerging markets.
As part of its coverage, the report breaks down the entire IVD market for the following regions:
The report does not merely report figures absent context. It describes the competitive workings of the diagnostics industry, combining a competitor, product, regulatory and payor decision analysis. In addition to providing authoritative market estimates for IVD market segments, this unique report seeks to explain why market events are occurring. The report delves into fast- breaking trends in in vitro diagnostics and distinguishes between company PR and actual market reality.
As part of its coverage, the following trends are detailed in the report:
The report contains detailed profiles of the top players in IVD. Profiling in this report describes the developments in each significant division of their business. A number of secondary players are also extensively profiled, as well as specialty companies with expertise in one testing area.
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the IVD industry.
New Report Says In Vitro Diagnostic Market Reaches 54.6Billion
NEW YORK, N.Y. - The world marketfor diagnostics is estimated at $54.6 billion in 2013, according to KaloramaInformation. The market is expected to grow 4% annually and reach $65billion by 2018. This includes all laboratory and hospital-basedproducts, and OTC product sales. Kalorama revealed the market estimatesin its biennial survey of the IVD industry, The Worldwide Market for In Vitro DiagnosticTests, 9th Edition.
“Not three years ago it would havebeen almost inconceivable to see research technologies such as genomesequencing and mass spectroscopy play a pivotal role in improving labmedicine,” said Shara Rosen, Kalorama’s lead diagnostic analyst and the authorof the report. “Their influence is felt in personalized medicine,inherited diseases, pathogen detection, antibiotic resistance testing, bloodbanking and much more to come.”
Commentary on LDT Regulatory changes
The 8th edition of this report published in 2012 discussed the possible regulation of lab developed tests (LDTs). Well in 2014, the possible is a reality. In the beginning …. September 2006, the FDA issued a draft guidance on analyte specific reagents (ASRs), which are commercially available reagents used in lab developed tests (LDTs). The FDA decided to use enforcement discretion and excluded laboratory-developed tests from the ASR rule based on confidence in a high-complexity laboratory’s ability to use them.
LDTs are developed within the laboratory and do not currently require FDA clearance. They are currently regulated under CLIA as highly complex tests and thus are subject to in-house validation and cGMP quality documentation requirements.
August 1, 2014, the FDA announced plans to implement a risk-based regulation of laboratory-developed tests over the course of nine years. The FDA also said it plans to release its draft guidance in 60 days. The FDA’s announcement comes out at a time when the agency has come under increasing pressure from congressional and federal advisory committees, consumer groups and the industry to expand its oversight of in-house developed testing. The FDA announcement stated that LDTs have become an intrinsic part of personalized medicine and that inaccurate test results could cause patients to seek unnecessary treatment, or delay and sometimes forgo treatment altogether. Further the policy change “demonstrates the agency's commitment to personalized medicine, which depends on accurate and reliable tests to get the right treatment to the right patient.”
The statement also stated that the FDA would implement the regulations over a nine-year period and would focus on tests where a wrong result would pose the highest risk for patients. It also said it would exempt tests for which there is no approved alternative and tests for rare diseases.
The FDA says it intends to require pre-market review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion diagnostics currently on the market. The draft guidance also proposed that LDTs would be classified as Class I, II, or III depending on risk. The agency will first focus on high-risk devices that have the same intended use as cleared or approved companion diagnostics.
It is expected that the classification may take the form of a proposal submitted by the American College of Medical Genetics and Genomics. In 3013, the American College of Medical Genetics and Genomics (ACMG, www.acmg.net/) released a framework to standardize risk classification of laboratory developed tests (LDTs) for inherited conditions. The approach represents a regulatory context that the group hopes will be used to assist federal agencies and policymakers. The ACMG presented risk-based classification that aligns risk with the medical decisions made based on the test results and how an incorrect result or interpretation might impact patients.
Related Reports:Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)
Oct 30, 2014 - KLI5367934 - $3,995.00
Syringe Infusion Pumps: World Market Analysis
Oct 30, 2014 - KLI5370043 - $1,500.00
Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
Oct 10, 2014 - KLI5348440 - $4,200.00
Big Data and Healthcare
Aug 26, 2014 - KLI5317106 - $750.00
Physician Office Laboratory (POL) Markets, 3rd Edition (Markets for Office-Based Chemistry, Glucose, Coagulation PT, Autoimmune, HIV, Hep, Cardiac Markers, PSA, Flu, HbA1c, Hematology, FOB and Other Tests)
Aug 15, 2014 - KLI5314670 - $3,995.00
The World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral Foods), 6th Edition
Jul 16, 2014 - KLI5296709 - $3,995.00
Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets)
Jul 14, 2014 - KLI5295379 - $2,995.00
The World Market for Flow Cytometry in IVD Applications
Jun 16, 2014 - KLI5271977 - $1,995.00
The Global Market for Medical Devices, 5th Edition
May 28, 2014 - KLI5254463 - $2,500.00
Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments
May 7, 2014 - KLI5239832 - $4,500.00
Questions?Contact a research specialist >
Most Popular ResearchThe Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition Results of The 2012 Kalorama IVD Procedure Count: White Paper The World Market for Point of Care (POC) Diagnostics World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) The United States Market for In Vitro Diagnostic Tests IVD Procedure Volume and Pricing Analysis